Trial Profile
Efficacy of bendamustine in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma after failure or suboptimal responses to nivolumab therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2018
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association